<DOC>
	<DOCNO>NCT01755390</DOCNO>
	<brief_summary>Primary Objective : - To determine maximum tolerate dose ( MTD ) dose-limiting toxicity ( DLT ) XRP6258 give weekly 1-hour intravenous ( i.v . ) infusion first 4 consecutive week 5-week treatment cycle ( Day 1 , Day 8 , Day 15 , Day 22 5-week treatment cycle ) . Secondary Objectives : - To define safety profile drug - To establish recommend dose time interval future Phase II trial - To determine pharmacokinetic ( PK ) profile XRP6258 man - To assess absolute oral bioavailability XRP6258 i.v . recommend dose ( follow Protocol Amendment No . 2 ) - To look evidence antitumor activity</brief_summary>
	<brief_title>A Dose Finding Study XRP6258 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>The duration study include follow period : - Pretreatment : 28 7 day first infusion - Treatment : Weekly first four consecutive week 5-week treatment cycle - Post-treatment : 3 - 4 week last infusion . Treatment may continue disease progression unacceptable toxicity patient refusal .</detailed_description>
	<criteria>Inclusion criterion : 1 . Signed informed consent prior begin protocol specific procedures 2 . Histologically proven cancer first diagnosis . At study entry , desirable require histological cytological proof metastasis case 1 single metastatic target lesion . 3 . Advanced neoplastic disease refractory conventional treatment standard therapy exist 4 . Progressive disease 5 . Age 1870 year 6 . ECOG ( Eastern Cooperative Oncology Group ) performance status 0 2 7 . Off previous anticancer ( radio chemo ) therapy least 4 week 6 week prior nitrosoureas , mitomycin C ; recovery toxic effect prior treatment ( Grade ≤1 , except alopecia grade ) 8 . Off previous immunotherapy least 1 week provide patient residual sign toxicity 9 . Adequate organ function include : neutrophil ≥2.0 × 109/L ; platelet ≥100 × 109/L , creatinine &lt; 120 μmol/L ( borderline creatinine value , creatinine clearance ≥60 mL/min ) ; total bilirubin within normal limit ; alanine aminotransferase ( ALT ) /aspartate aminotransferase ( AST ) /alkaline phosphatase ( ALP ) ≤2.5fold upper normal limit institutional norm ( ALP ≤2.5 UNL ) 10 . Patients register trial treat follow participate center 11 . Patients receive previous treatment paclitaxel docetaxel could include provide residual sign taxane toxicity ( except alopecia grade peripheral neuropathy Grade 1 ) 1 . Hematological malignancy 2 . Pregnant lactate woman woman childbearing potential ( eg , use adequate contraception ) 3 . Symptomatic brain metastasis 4 . Previous extensive radiotherapy ( &gt; 20 % bone marrow area ) 5 . Current peripheral neuropathy origin include significant residual symptom due use eg , vincaalkaloids platinum ≥Grade 2 accord National Cancer Institute common terminology criterion adverse event . 6 . Other serious illness medical condition : Congestive heart failure angina pectoris even medically control , previous history myocardial infarction within 1 year study entry , uncontrolled hypertension arrhythmia Existence significant neurological psychiatric disorder include dementia seizure Active infection Uncontrolled peptic ulcer , unstable diabetes mellitus , contraindication use corticosteroid 7 . Concurrent treatment experimental drug . Participation another clinical trial investigational drug within 30 day prior patient registration 8 . Concurrent treatment anticancer therapy 9 . Concomitant radiotherapy 10 . Concomitant treatment corticosteroid . However , patient receive chronic treatment corticosteroid ( ≤20 mg methylprednisolone ≤4 mg dexamethasone equivalent dose corticosteroid ) , whatever reason , eligible . 11 . More 2 prior chemotherapy regimen contain mitomycin C nitrosoureas 12 . More 2 prior chemotherapy regimen advance disease 13 . Prior history severe allergic reaction docetaxel paclitaxel 14 . Prior intensive chemotherapy autologous stem cell rescue The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2012</verification_date>
</DOC>